Company news
Exagen Inc. news in 2022
Exagen Inc.'s news releases, calls and decks from 2022, newest first.
Exagen Inc. Reports Third Quarter 2022 Results
November 13, 2022
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
October 30, 2022
Exagen Announces Appointment of John Aballi as CEO
October 16, 2022
Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
October 3, 2022
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
September 19, 2022
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
August 31, 2022
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
August 3, 2022
Exagen Inc. Reports Second Quarter 2022 Results
August 3, 2022
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 24, 2022
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
July 20, 2022
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
July 4, 2022
Exagen Inc. Expands Coverage with MediNcrease
June 8, 2022
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
May 25, 2022
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
May 15, 2022
Exagen Inc. Reports First Quarter 2022 Results
May 10, 2022
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
May 10, 2022
Exagen Announces Five-Week Campaign for Lupus Awareness Month
April 30, 2022
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
April 24, 2022
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
April 19, 2022
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
March 29, 2022
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 21, 2022
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
March 21, 2022
Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
March 15, 2022
Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
March 8, 2022
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 7, 2022
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 1, 2022
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
January 8, 2022
Calls in 2022
Decks in 2022
- Investor Presentation (January 2022)
Investor deck · 17 slides · Jan 10, 2022